Related Experiment Video
Updated: May 24, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Interferon alpha 2b in the treatment of uveitic cystoid macular edema
Nicholas J Butler1, Eric B Suhler, James T Rosenbaum
1Wilmer Eye Institute, Ophthalmology, Baltimore, Maryland, United States.
Purpose:
To determine the efficacy of interferon alpha 2b in the treatment of refractory, uveitic cystoid macular edema (CME).
Methods:
Retrospective chart review of 4 patients attending the uveitis clinic at the Casey Eye Institute, Oregon Health & Science University.
Results:
All 4 patients had uveitis and refractory CME, resistant to a variety of immunosuppressants. All patients, except one with severe scleral thinning, had tried and failed therapy with locally injected corticosteroids. Treatment with systemic interferon alpha 2b produced dramatic improvement in CME (central macular thickness: 563 to 267 µm, p = .002) and visual acuity (logMAR: +0.81 to +0.45, p = .0004) in all 4 cases. All patients have been able to reduce the interferon dosage, but none has discontinued it completely. All patients had some mild adverse response that did not necessitate stopping therapy.
Conclusions:
Interferon alpha 2b is an effective option to treat refractory CME secondary to uveitis.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Inhibitors of Viral Protein Synthesis
Angle Closure Glaucoma: Treatment
Nephrotic Syndrome II : Assessment and Medical Management
Diabetic Retinopathy
